Rimegepant 75mg Orally Disintegrating Tablets (ODT)

DRUG2 trials

Sponsors

Pfizer, Shi Tianming

Conditions

Acute MigraineDizziness

Phase 2

Efficacy and Safety of Rimegepant for Acute Dizziness

Not yet recruitingNCT07435090

Shi TianmingDizziness

Start: 2026-03-20End: 2028-06-30Target: 370Updated: 2026-02-27

Phase 3

A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

CompletedNCT05371652

PfizerAcute Migraine

Start: 2022-05-19End: 2024-02-06Updated: 2025-02-20

Related Papers

Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.

2025-10-091 citations

Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

The Journal of Headache and Pain2024-04-1625 citations